【康方生物:依沃西头对头帕博利珠单抗Ⅲ期临床研究结果在《柳叶刀》发表】 近日,康方生物自主研发的全球首创PD-1/VEGF双特异性抗体新药依沃西单药对比帕博利珠单抗单药一线治疗PD-L1表达阳性的局部晚期或转移性非小细胞肺癌的注册性Ⅲ期临床研究(HARMONi-2/AK112-303)的研究数据,在国际顶级医学期刊《柳叶刀》发表。

金融界
07 Mar
近日,康方生物自主研发的全球首创PD-1/VEGF双特异性抗体新药依沃西单药对比帕博利珠单抗单药一线治疗PD-L1表达阳性的局部晚期或转移性非小细胞肺癌的注册性Ⅲ期临床研究(HARMONi-2/AK112-303)的研究数据,在国际顶级医学期刊《柳叶刀》发表。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10